JF
Therapeutic Areas
Adaptimmune Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| ADP-600 | Synovial sarcoma, breast, NSCLC, gastroesophageal, melanoma, endometrial, ovarian, head & neck cancers (indications that express PRAME) | Indication-Enabling |
| ADP-520 | Hematological malignancies, acute myeloid leukemia (AML), lymphoma, renal cell carcinoma (RCC) (indications that express CD70) | Indication-Enabling |
| TECELRA | Cancer (platform/product portfolio name) | Sold/Transferred |
| Lete-cel | Cancer | Sold/Transferred |
| Afami-cel | Cancer | Sold/Transferred |
| Uza-cel | Cancer | Sold/Transferred |
Leadership Team at Adaptimmune Therapeutics
LM
Lawrence M. Alleva
Chairman and Non-Executive Director
C(
Christopher (Chris) Hill
Chief Executive Officer and Chief Financial Officer
GM
Garry Menzel, Ph.D.
Non-Executive Director
AR
Adrian Rawcliffe
Former Chief Executive Officer (departed Nov 2025)
W(
William (Bill) Bertrand
Former Chief Operating Officer (departed Nov 2025)
DM
David Mott
Former Chairman (resigned Nov 2025)
AA
Andrew Allen
Former Board Member (resigned Nov 2025)
AB
Ali Behbahani
Former Board Member (resigned Nov 2025)
PH
Priti Hegde
Former Board Member (resigned Nov 2025)
KH
Kristen Hege
Former Board Member (resigned Nov 2025)